Description
Tazemetostat
Each film-coated tablet contains Tazemetostat hydrobromide 228 mg equivalent to Tazemetostat … 200mg.
INDICATION
LuciTaze is a methyltransferase inhibitor indicated for the treatment of: • Adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. • Adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation test and who have received at least 2 prior systemic therapies. • Adult patients with relapsed or refractory follicular lymphoma who have no satisfactory alternative treatment options.
DOSAGE AND USE
• Recommended dosage is 800 mg taken orally twice daily with or without food. • Swallow tablets whole. Do not cut, crush, or chew tablets.
STORAGE
In a dry place and store at 20°C to 25°C.
MANUFACTURED AND MARKETED BY
LUCIUS PHARMACEUTICALS(LAO) CO., LTD. No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos
WARNING
Keep medicine out of reach of Children. Do not administer LuciTaze during Pregnancy and Lactation.
Reviews
There are no reviews yet.